印度通过创新举措, 打算成为全球制药业的领导者. India targets global pharma leadership through innovation initiatives.

印度制药2026年在新德里举行的一次大型会议, 主要关注该国向全球制药领导地位的转变. India Pharma 2026, a major conference in New Delhi, focused on the country's shift toward global leadership in pharmaceuticals. 卫生部长J.P.Nadda强调政府通过1万亿卢比的生物制药力量计划和PLI项目等举措推动创新. Health Minister JP Nadda highlighted the government's push for innovation through initiatives like the Rs 10,000 crore Biopharma Shakti Initiative and PLI schemes. 印度将从仿制药生产转向先进疗法, 以不断增长的生物类似药市场为目标. Officials emphasized India's transition from generic manufacturing to advanced therapies, targeting the growing biosimilars market.